TickerFacts.

QuidelOrtho Corp (QDEL): Long-Term Debt

Annual figures by period end, from SEC filings.

$2.70B
As of 2025-12-28
+0.6%
3-year compound annual growth
2023-01-01: $2.65B2023-12-31: $2.42B2024-12-29: $2.49B2025-12-28: $2.70B$2.70B
2023-01-01 Long-Term Debt (USD) 2025-12-28
Period endedLong-Term DebtChange YoYSource filing
2025-12-28$2.70B+8.4%2026-02-19, Balance as of period end
2024-12-29$2.49B+2.7%2025-02-27, Balance as of period end
2023-12-31$2.42B-8.5%2024-08-01, Balance as of period end
2023-01-01, Fiscal 2022$2.65Bn/a2023-02-23, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
QuidelOrtho Corp (QDEL)2025-12-28$2.70B+8.4%
Idexx Laboratories Inc (IDXX)2025-12-31$450.00M-27.2%
Myriad Genetics Inc (MYGN)2025-12-31$119.90Mn/a
Alpha Teknova, Inc. (TKNO)2025-12-31$13.12M+39.0%
Immucell Corp (ICCC)2025-12-31$9.10Mn/a
Aspira Women's Health Inc. (AWHL)2025-12-31$1.28M-15.3%
Volitionrx Ltd (VNRX)2025-12-31$6.71M+39.4%

Compare QDEL, IDXX, MYGN, TKNO side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗